Expansions of tumor-reactive Vdelta1 gamma-delta T cells in
newly diagnosed patients with chronic myeloid leukemia

J 2023

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

KNIGHT, Andrea; Martin PISKÁČEK; Michal JURAJDA; Jiřina PROCHÁZKOVÁ; Zdeněk RÁČIL et. al.

Základní údaje

Originální název

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

Autoři

KNIGHT, Andrea (203 Česká republika, garant, domácí); Martin PISKÁČEK (40 Rakousko, domácí); Michal JURAJDA (203 Česká republika, domácí); Jiřina PROCHÁZKOVÁ (203 Česká republika, domácí); Zdeněk RÁČIL (203 Česká republika); Daniela ŽÁČKOVÁ (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Cancer immunology, immunotherapy, NEW YORK, SPRINGER, 2023, 0340-7004

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.600

Kód RIV

RIV/00216224:14110/23:00130077

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00262-022-03312-3

UT WoS

000884524700001

EID Scopus

2-s2.0-85141983201

Klíčová slova anglicky

Gamma-delta T cells; Chronic myeloid leukemia; Tumor immunotherapy; Clonality

Štítky

14110212, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 1. 2024 10:20, Mgr. Tereza Miškechová

Anotace

V originále

Recent studies have underscored the importance of gamma-delta (γδ) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we analyzed Vδ1 and Vδ2 γδ T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients (n = 40) who had initiated tyrosine kinase inhibitor (TKI) therapy including imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4). Patient peripheral blood samples were analyzed at diagnosis and monitored prospectively at 3, 6, 12 and 18 months post-TKI. γδ T cells isolated from healthy donors and CML patients were used against K562, LAMA-84 and KYO-1 cell lines and against primary CML cells in cytotoxicity assays. We found large expansions of Vδ1 and Vδ2 T cells in patients at diagnosis compared to age-matched healthy donors (n = 40) (p < 0.0001). The γδ T cell reconstitution in patients on imatinib and also on nilotinib showed significant reductions of Vδ1 T cell and Vδ2 T cell absolute counts at 3 months compared to diagnosis. Importantly, Vδ1 and Vδ2 T absolute cell counts remained at normal levels from 3 months throughout the follow-up. Next, we observed susceptibility to specific lysis of primary CML tumor cells by Vδ1 T cells from healthy donors. Furthermore, we determined inherent cytotoxic reactivity by autologous patients’ Vδ1 T lymphocytes against primary CML tumor cells. Finally, the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI. Our results provide further evidence into γδ T cell antileukemia immunity in CML that might be beneficial for long-term disease control and treatment outcome.

Návaznosti

NV19-05-00410, projekt VaV

Název: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme

Investor: Ministerstvo zdravotnictví ČR, Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme

Citovat

KNIGHT, Andrea; Martin PISKÁČEK; Michal JURAJDA; Jiřina PROCHÁZKOVÁ; Zdeněk RÁČIL; Daniela ŽÁČKOVÁ a Jiří MAYER. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia. Cancer immunology, immunotherapy. NEW YORK: SPRINGER, 2023, roč. 72, č. 5, s. 1209-1224. ISSN 0340-7004. Dostupné z: https://dx.doi.org/10.1007/s00262-022-03312-3.

@article{2233738,
   author = {Knight, Andrea and Piskáček, Martin and Jurajda, Michal and Procházková, Jiřina and Ráčil, Zdeněk and Žáčková, Daniela and Mayer, Jiří},
   article_location = {NEW YORK},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s00262-022-03312-3},
   keywords = {Gamma-delta T cells; Chronic myeloid leukemia; Tumor immunotherapy; Clonality},
   language = {eng},
   issn = {0340-7004},
   journal = {Cancer immunology, immunotherapy},
   title = {Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia},
   url = {https://link.springer.com/article/10.1007/s00262-022-03312-3},
   volume = {72},
   year = {2023}
}

TY  - JOUR
ID  - 2233738
AU  - Knight, Andrea - Piskáček, Martin - Jurajda, Michal - Procházková, Jiřina - Ráčil, Zdeněk - Žáčková, Daniela - Mayer, Jiří
PY  - 2023
TI  - Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
JF  - Cancer immunology, immunotherapy
VL  - 72
IS  - 5
SP  - 1209-1224
EP  - 1209-1224
PB  - SPRINGER
SN  - 03407004
KW  - Gamma-delta T cells
KW  - Chronic myeloid leukemia
KW  - Tumor immunotherapy
KW  - Clonality
UR  - https://link.springer.com/article/10.1007/s00262-022-03312-3
N2  - Recent studies have underscored the importance of gamma-delta (γδ) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we analyzed Vδ1 and Vδ2 γδ T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients (n = 40) who had initiated tyrosine kinase inhibitor (TKI) therapy including imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4). Patient peripheral blood samples were analyzed at diagnosis and monitored prospectively at 3, 6, 12 and 18 months post-TKI. γδ T cells isolated from healthy donors and CML patients were used against K562, LAMA-84 and KYO-1 cell lines and against primary CML cells in cytotoxicity assays. We found large expansions of Vδ1 and Vδ2 T cells in patients at diagnosis compared to age-matched healthy donors (n = 40) (p < 0.0001). The γδ T cell reconstitution in patients on imatinib and also on nilotinib showed significant reductions of Vδ1 T cell and Vδ2 T cell absolute counts at 3 months compared to diagnosis. Importantly, Vδ1 and Vδ2 T absolute cell counts remained at normal levels from 3 months throughout the follow-up. Next, we observed susceptibility to specific lysis of primary CML tumor cells by Vδ1 T cells from healthy donors. Furthermore, we determined inherent cytotoxic reactivity by autologous patients’ Vδ1 T lymphocytes against primary CML tumor cells. Finally, the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI. Our results provide further evidence into γδ T cell antileukemia immunity in CML that might be beneficial for long-term disease control and treatment outcome.
ER  -

KNIGHT, Andrea; Martin PISKÁČEK; Michal JURAJDA; Jiřina PROCHÁZKOVÁ; Zdeněk RÁČIL; Daniela ŽÁČKOVÁ a Jiří MAYER. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia. \textit{Cancer immunology, immunotherapy}. NEW YORK: SPRINGER, 2023, roč.~72, č.~5, s.~1209-1224. ISSN~0340-7004. Dostupné z: https://dx.doi.org/10.1007/s00262-022-03312-3.

Přehled o publikaci